Valuation: Opus Genetics, Inc.

Market Cap 276M 247M 229M 207M 387M 26.28B 394M 2.75B 1.09B 13.74B 1.04B 1.01B 43.52B P/E 2026 *
-3.39x
P/E 2027 * -4.68x
Enterprise Value 276M 247M 229M 207M 387M 26.28B 394M 2.75B 1.09B 13.74B 1.04B 1.01B 43.52B EV / Sales 2026 *
20.1x
EV / Sales 2027 * 20.3x
Free-Float
87.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day-4.32%
1 week-13.09%
Current month-31.40%
1 month-30.25%
3 months+7.79%
6 months-36.52%
Current year+65.17%
1 week 3.23
Extreme 3.23
4.22
1 month 3.23
Extreme 3.23
5.32
Current year 1.88
Extreme 1.88
7.07
1 year 1.7
Extreme 1.7
7.07
3 years 0.65
Extreme 0.65
7.07
5 years 0.65
Extreme 0.65
7.07
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26
The Foundation Fighting Blindness, Inc.
SellCompany -556,000 0.6683%
9/9/26 Exercice

Chief Executive Officer

859,855 1.0335%
8/9/26 Exercice

Chairman

1,568,628 1.8855%
Change 5-day change 1-year change 3-year change Capi.($)
-4.32%-13.09%+66.83%+19.21% 276M
+0.45%+3.13%+54.96%+125.16% 1,140B
+0.94%+4.93%+39.86%+78.72% 641B
+0.39%+1.44%+25.77%+97.48% 507B
-0.16%+1.33%+47.76%+66.18% 383B
-3.21%-2.10%+60.72%+33.22% 347B
+1.45%+2.25%+25.38%+54.42% 293B
-0.04%+1.81%+2.39%+26.89% 266B
+1.22%+4.63%+52.40%+64.85% 240B
+1.70%+3.67%+31.21%+102.15% 197B
Average -0.06%+1.32%+40.73%+66.83% 401.41B
Weighted average by Cap. +0.37%+2.98%+41.71%+84.26%

Financials

2026 *2027 *
Net sales 13.75M 12.3M 11.38M 10.3M 19.28M 1.31B 19.59M 137M 54.15M 684M 51.61M 50.5M 2.17B 13.62M 12.18M 11.27M 10.21M 19.1M 1.3B 19.41M 136M 53.65M 678M 51.14M 50.04M 2.15B
Net income -91.21M -81.56M -75.46M -68.32M -128M -8.68B -130M -908M -359M -4.54B -342M -335M -14.37B -69.08M -61.77M -57.15M -51.74M -96.84M -6.57B -98.43M -688M -272M -3.44B -259M -254M -10.88B
Net Debt - -
Projected Income Statement - Annual - Opus Genetics, Inc.
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26/10/26 USD 3.320 -4.32% 1,520,404
23/10/26 USD 3.470 -9.16% 1,118,007
22/10/26 USD 3.820 -7.17% 894,736
21/10/26 USD 4.115 +2.62% 1,355,925
20/10/26 USD 4.010 +4.97% 1,461,227
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Opus Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
3.320USD
Average target price
13.47USD
Spread / Average Target
+305.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Opus Genetics, Inc.